Evidence map›Paper›PMID 37996881›Full record

ReviewAIDS research and therapy2023

Standard of care in advanced HIV disease: review of HIV treatment guidelines in six sub-Saharan African countries.

Thomas C Scheier, Nabila Youssouf, Mosepele Mosepele, Cecilia Kanyama, Olukemi Adekanmbi, Sulaiman Lakoh, Conrad K Muzoora, Graeme Meintjes, Dominik Mertz, John W Eikelboom and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in AIDS research and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 7 countries.

Thomas C ScheierPopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada.
Nabila YoussoufBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Mosepele MosepeleBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Cecilia KanyamaUniversity of North Carolina Project-Malawi, Lilongwe, Malawi.
Olukemi AdekanmbiDepartment of Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Sulaiman LakohCollege of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone.
Conrad K MuzooraDepartment of Internal Medicine Faculty of Medicine Mbarara, University of Science and Technology Mbarara, Mbarara, Uganda.
Graeme MeintjesCentre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Dominik MertzPopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada.
John W EikelboomPopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada.
Sean WassermanCentre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. swasserm@sgul.ac.uk.
Botswana Harvard AIDS Institute Partnership · BWMcMaster University · CAUniversity of Cape Town · ZAHamilton Health Sciences · CAMbarara University of Science and Technology · UGUniversity of Ibadan · NGUniversity of Malawi · MWUniversity of Sierra Leone · SL

Funding

Characterizing the pharmacokinetics of high dose rifampicin and linezolid in a randomized controlled trial for HIV-associated tuberculous meningitisK43TW011421 · FIC · UNIVERSITY OF CAPE TOWN · PI WASSERMAN, SEAN ADAM · 2019 to 2022
$404k
FIC NIH HHS K43 TW011421NIH HHS K43TW011421Wellcome Trust
6 · The paper itself

Abstract

backgroundThe World Health Organization (WHO) recommends an evidence-based package of care to reduce mortality and morbidity among people with advanced HIV disease (AHD). Adoption of these recommendations by national guidelines in sub-Saharan Africa is poorly documented. We aimed to review national guidelines for AHD management across six selected countries in sub-Saharan Africa for benchmarking against the 2021 WHO recommendations.

methodsWe reviewed national guidelines from six countries participating in an ongoing randomized controlled trial recruiting people with AHD. We extracted information addressing 18 items of AHD diagnosis and management across the following domains: [1] Definition of AHD, [2] Screening, [3] Prophylaxis, [4] Supportive care, and [5] HIV treatment. Data from national guideline documents were compared to the 2021 WHO consolidated guidelines on HIV and an agreement score was produced to evaluate extent of guideline adoption.

resultsThe distribution of categories of agreement varied for the national documents. Four of the six countries addressed all 18 items (Malawi, Nigeria, Sierra Leone, Uganda). Overall agreement with the WHO 2021 guidelines ranged from 9 to 15.5 out of 18 possible points: Malawi 15.5 points, Nigeria, and Sierra Leone 14.5 points, South Africa 13.5 points, Uganda 13.0 points and Botswana with 9.0 points. Most inconsistencies were reported for the delay of antiretroviral therapy (ART) in presence of opportunistic diseases. None of the six national guidelines aligned with WHO recommendations around ART timing in patients with tuberculosis. Agreement correlated with the year of publication of the national guideline.

conclusionNational guidelines addressing the care of advanced HIV disease in sub-Saharan Africa are available. Besides optimal timing for start of ART in presence of tuberculosis, most national recommendations are in line with the 2021 WHO standards.

Indexed as

HIV InfectionsTuberculosisHumansLongitudinal StudiesSouth AfricaStandard of CareAdvanced HIV diseaseREVIVE trialStandard of careSub-Saharan AfricaWHO

Identifiers

PMID37996881
PMCPMC10668471
OpenAlexW4388941539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.